A LIMS1 gene variant appeared to coincide with increased risk of allograft rejection in kidney transplant recipients.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
The companies will develop an IVD system based on the MiniSeq initially to diagnose hereditary kidney disease.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
A new analysis found kidney disease-related pathogenic or likely pathogenic variants in exomes for roughly 9 percent of individuals with chronic kidney disease.
The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.
The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.